Side effects

Nausea on GLP-1 medications

Pending medical review

By Joshua Nichvolodoff · Fact-checked against sources November 2, 2026 · Next review due May 1, 2027

Clinical review: not yet reviewed by a clinician. How review works · Editorial policy

Nausea is the side effect people ask about most with semaglutide and tirzepatide. Here is how often it was reported in the trials behind the labels, what the labels say about when it tends to happen, and the signs that mean calling your prescriber — without guessing what is "normal" for you.

How often it was reported

People reporting nausea in the trials behind each US label[1][2][3][4]
ItemOn the medicineOn placebo
Wegovy 2.4 mg (weight management)44%16%
Zepbound 5–15 mg (weight management)25–29%8%
Ozempic 0.5 mg / 1 mg (type 2 diabetes)15.8% / 20.3%6.1%
Mounjaro 5–15 mg (type 2 diabetes)12–18%4%
Different trials, populations and doses — compare within a row, not across rows.

Vomiting was less common: 24% on Wegovy versus 6% on placebo, and 8–13% on Zepbound versus 2%[1][2].

When it tends to happen, and how long it lasted in trials

The labels say most reports came during dose escalation; the Zepbound and Mounjaro labels add that these events decreased over time[2][4]. In a pooled analysis of the STEP 1–3 trials of semaglutide 2.4 mg, the median nausea episode lasted 8 days and the median vomiting episode 2 days, and 98.1% of stomach-related events were mild or moderate[5]. These are averages across thousands of people; they can't predict how it will go for you.

Across the SURMOUNT-1 to -4 trials of tirzepatide, most stomach-related side effects were not serious and occurred during dose escalation, and weight loss was similar with or without nausea[6].

How many people stopped because of it

In STEP 1, 4.5% of people on semaglutide stopped treatment because of stomach-related events, versus 0.8% on placebo[7]. In SURMOUNT-1, the most common side effects of tirzepatide were stomach-related and mostly mild to moderate[8].

What may help

A 2025 joint nutrition advisory suggests smaller, more frequent meals and avoiding fatty or high-fibre foods in the first days of treatment, and notes that large meals make vomiting more likely[9]. Anything about your dose or schedule is a conversation for your prescriber.

When to call your prescriber

The Medication Guides say to tell a healthcare provider right away about nausea, vomiting or diarrhea that does not go away, because losing fluids can lead to kidney problems[1][2]. Severe stomach pain that will not go away, with or without vomiting — sometimes felt through to the back — can be a sign of pancreatitis: the labels say to stop the medicine and call a healthcare provider right away[1].

General information from product labels and published trials — not medical advice.

Sources

  1. WEGOVY (semaglutide) injection and tablets — prescribing information and Medication Guide (revised 06/2026). U.S. Food and Drug Administration, June 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf. Accessed November 2, 2026. Back to the text
  2. ZEPBOUND (tirzepatide) injection — prescribing information and Medication Guide (revised 04/2026). U.S. Food and Drug Administration, April 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s050lbl.pdf. Accessed November 2, 2026. Back to the text
  3. OZEMPIC (semaglutide) injection — prescribing information (revised 05/2026). U.S. Food and Drug Administration, May 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/209637s038lbl.pdf. Accessed November 2, 2026. Back to the text
  4. MOUNJARO (tirzepatide) injection — prescribing information (revised 08/2026). U.S. Food and Drug Administration, August 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215866s044s045lbl.pdf. Accessed November 2, 2026. Back to the text
  5. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism, January 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236/ · DOI 10.1111/dom.14551 · PMID 34514682. Accessed November 2, 2026. Back to the text
  6. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism, April 2025. https://pubmed.ncbi.nlm.nih.gov/39789843/ · DOI 10.1111/dom.16176 · PMID 39789843. Accessed November 2, 2026. Back to the text
  7. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, March 18, 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/ · DOI 10.1056/NEJMoa2032183 · PMID 33567185. Accessed November 2, 2026. Back to the text
  8. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, July 21, 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/ · DOI 10.1056/NEJMoa2206038 · PMID 35658024. Accessed November 2, 2026. Back to the text
  9. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Lifestyle Medicine, May 30, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12125019/ · DOI 10.1177/15598276251344827 · PMID 40452753. Accessed November 2, 2026. Back to the text

Figures marked “as reported” are historical: they show what the source said on that date, not today's price or rule.

Changes to this page

  • — First published.

Substantive corrections are also logged at corrections.

← More in Side effects